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Oral Presentations 33patients (5%) developed severe HC by day 1100 after HSCT.
There were 22 (4.2%) cases in related donor (RD) recipients, 18
(4.5%) cases in unrelated donor (URD) recipients and 32 (7.4%)
cases in URD umbilical cord blood (UCB) recipients. In multivar-
iate analysis, factors associated with an increased risk of severe HC
included age.18 yrs (RR 2.4 vs. 1.0 in those\18 yrs [95% CI 1.7 –
3.6, p\ .01]), receiving busulfan as part of the conditioning regimen
(RR 2.6 vs. 1.0 in those whose conditioning regimen did not include
busulfan [95% CI 1.6 – 4.3, p\ .01]), receiving an URD or UCB
stem cells (RR 1.7, 95% CI 1.2 – 2.3, p\ .01 and RR 1.5, 95%
CI 1.0 – 2.2, p5 .05, respectively when compared to RD bone mar-
row) and receiving myeloablative conditioning (RR 1.0 vs. 0.6 for
nonmyeloablative conditioning (p 5 .03). With respect to patient
diagnosis, Fanconi anemia was associated with a higher risk of se-
vere HC (RR 2.1 vs. 1.0 for SAA/Immune deficiencies/Hematologic
disorders, [95% CI 1.0 – 4.3, p.04]) while a diagnosis of storage dis-
order was associated with a decreased risk of severe HC (RR 0.4 vs.
1.0 for SAA/Immune deficiencies/Hematologic disorders, [95% CI
0.2 – 0.9, p.03]).
The results of our study examining patients transplanted in the
last decade show a similar incidence of severe HC as reported in pre-
vious studies from our institution. Risk factors (older age, URD or
UCB and the use of Busulfan) are also similar except the presence of
grades II-IV GVHD is not significantly associated with the devel-
opment of severe HC in the current analysis. Our current results
also indicate that nonmyeloablative transplants are protective with
regard to the development of severe HC. Despite regular use of pro-
phylactic measures, severe HC remains a significant problem after
HSCT and more effective modalities to prevent and treat it are nee-
ded.83
DOES RESPIRATORY MUSCLE DYSFUNCTION PRIOR TO ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION INFLUENCE THE RISK FOR
MORTALITY AFTER TRANSPLANT?
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The prevalence of restrictive lung disease and respiratory muscle
weakness (RMW) prior to allogeneic hematopoietic cell transplant
(aHCT) and their relationship with HCT outcomes is unknown.
We conducted a 12-year retrospective cohort study to determine
the prevalence of pulmonary restriction prior to HCT, and assessed
whether prior pulmonary restriction, in particular, pulmonary re-
striction due to RMW, is associated with an increased risk of devel-
oping early respiratory failure and mortality.
Methods: All patients.15 yrs old who received an aHCT at our
center between 1990 and 2001 and had pulmonary function testing
(PFT) prior to transplant were eligible for analysis (n5 2677). A re-
strictive lung function pattern was defined as a total lung capacity
(TLC) \80% of predicted normal. All patients with restriction
had their pre-transplant chest x-rays and/or computed tomography
scans reviewed by three pulmonologists to determine whether pa-
renchymal abnormalities were absent, unlikely to cause restriction,
or highly likely to cause restriction. Multivariate Cox-proportional
hazard analysis was performed to assess the association between re-
striction and two post-transplant outcomes, early respiratory failure
and all cause mortality. Results: There were 2677 patients with
a mean age of 42 6 12 yrs and mean body mass index of 26 6 5
k/m2. 41.8% (n 5 1118) were female. Prevalence of pre-transplant
pulmonary restriction was high in all malignancy groups (range, 5–
40%) regardless of age or nutritional status. High risk pre-trans-
plant disease was significantly associated with restriction (OR 52.9, p\0.001). Review of chest imaging of all patients with restric-
tion revealed that 80% (n5 156) had no radiographic abnormalities
likely to cause restriction. Comparison of patients with restriction
but no radiographic abnormalities, to nonrestricted patients, re-
vealed a significant stepwise increase in risk for mortality with pro-
gressively worse pulmonary restriction (TLC range, 24-\70%;
hazard ratio range, 1.8–4.1 p\ 0.001 all). Conclusions: Presence
of pre-transplant pulmonary restriction is associated with higher
mortality risk after aHCT. The majority of these restrictive cases
are unlikely related to lung parenchymal abnormalities suggesting
that respiratory muscle weakness may be a previously unrecognized
risk factor for respiratory failure and mortality after transplant.84
IMPACT OF BRONCHO-ALVEOLAR LAVAGE ON THE DIAGNOSIS AND
MANAGEMENT OF PULMONARY COMPLICATIONS POST TRANSPLANT
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The role of fiberoptic bronchoscopy with broncho-alveolar la-
vage (BAL) in hematopoeitic stem cell transplantation (HSCT)
has been examined in a number of small retrospective studies.
The largest review of BAL data to date is now reported. Between
2001–2007, 1507 patients underwent HSCT at the University of
Michigan Medical Center. Of the 1507 patients, 300 (19.7%) un-
derwent a BAL procedure, including 9.7% of autologous, and
30.4% of allogeneic transplant recipients. Four hundred forty
four BAL were performed, 347 following an allogeneic, and 97 fol-
lowing an autologous HSCT.
Results: Potential pathogens were identified in 117 (26.4%)
cases, with infections due to fungi (n5 50), viruses (n5 38), bacteria
(n5 38), mycobacterium (n5 10), and PCP (n5 6). In 30 BAL pro-
cedures, multiple pathogens were noted. Broncho-alveolar lavage
had the lowest yield within the first 30 days post allogeneic
HSCT, with 89.9% of BAL procedures negative during this time
period. At all time points, the likelihood of identifying a pathogen
was\ 35%. The BAL led to a change in medical management in
58% of cases, including modifications in antimicrobial therapy in
44% and modifications in corticosteroid therapy in 18%. Proce-
dural complications were rare, and included transient hypoxemia
(1.3%), hemorrhage (1.3%) and hypotension (0.2%). Radiographi-
cally, the presence of nodular lesions, ground glass opacifications,
and air space disease on chest CT were more frequently associated
with non-infectious BAL findings (Table). Only the appearance of
a tree in bud pattern was more likely to be associated with an infec-
tious etiology, primarily fungal disease.Conclusion:Broncho-alve-
olar lavage is a safe procedure in patients following HSCT
transplant, frequently modifying medical management. At all time
points, the yield for infectious pathogens is\35%, with non-infec-
tious etiologies common and associated with multiple radiographic
changes by CT.
CT findings and % of BAL with pathogen identified
Tree in Ground Air space
nodules (s) nodules (l) Bud glass disease1 BAL 26% 42% 64% 25% 18%
2 BAL 74% 58% 36% 75% 82%nodules (s)\ 1 cm; nodules (l) . 1 cm.
